RECRUITING

Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The main reason for this research study is to learn more about hydroxyurea and the treatment of sickle cell anemia (SCA). Hydroxyurea is a medication that has been studied for many years and has been shown to provide benefits for people with SCA. In this research study, the investigators hope to learn more about how to improve the dosing and monitoring of hydroxyurea and learn more about the long-term effects of hydroxyurea over time. Hydroxyurea is usually dosed based only on your weight. Our study will use a new way to select a starting dose that is based on how each patient absorbs hydroxyurea.

Official Title

Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)

Quick Facts

Study Start:2024-12-19
Study Completion:2028-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07177300

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:6 Months
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of sickle cell anemia (HbSS) or sickle-β0-thalassemia (HbSβ0)
  2. * Age 6 months at the time of enrollment
  3. * Clinical decision by patient, family, and healthcare provider to initiate hydroxyurea therapy
  1. * Current treatment with regularly scheduled blood transfusions
  2. * Sickle-hemoglobin C disease (HbSC), sickle-β+-thalassemia (HbSβ+)

Contacts and Locations

Study Contact

Wendi L. Long, Sr. Regulatory Specialist, BS, CCRC
CONTACT
513-803-3064
wendi.long@cchmc.org
Teresa Latham, Research Director, DrPH
CONTACT
(513) 803-7922
teresa.latham@cchmc.org

Principal Investigator

Charles T. Quinn, Professor of Pediatrics, M.D., M.S.
PRINCIPAL_INVESTIGATOR
Children's Hospital Medical Center, Cincinnati

Study Locations (Sites)

Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229
United States

Collaborators and Investigators

Sponsor: Children's Hospital Medical Center, Cincinnati

  • Charles T. Quinn, Professor of Pediatrics, M.D., M.S., PRINCIPAL_INVESTIGATOR, Children's Hospital Medical Center, Cincinnati

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-19
Study Completion Date2028-12

Study Record Updates

Study Start Date2024-12-19
Study Completion Date2028-12

Terms related to this study

Keywords Provided by Researchers

  • sickle cell anemia
  • SCD
  • sickle cell
  • hydroxyurea

Additional Relevant MeSH Terms

  • Sickle Cell Anemia (HbSS)
  • Sickle-β0-thalassemia (HbSβ0)